Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TSRO message board posts where the ticker symbol TSRO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TSRO SEC Filings

Filings Format Description Filing Date File/Film Number
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001104659-18-051944 Size: 15 KB
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001193125-18-247324 (34 Act)  Size: 71 KB
2018-08-13 005-86904
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001654954-18-008857 (34 Act)  Size: 69 KB
2018-08-13 005-86904
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-021817 Size: 8 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-049533 Size: 8 KB
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-18-006320 (34 Act)  Size: 7 MB
2018-08-03 001-35587
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-049183 (34 Act)  Size: 238 KB
2018-08-02 001-35587
8-K  Documents Current report, items 2.01 and 9.01
Acc-no: 0001104659-18-045794 (34 Act)  Size: 246 KB
2018-07-18 001-35587
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-006849 (34 Act)  Size: 10 KB
2018-07-11 001-35587
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-002073 (34 Act)  Size: 9 KB
2018-07-10 005-86904
More TSRO SEC Filings

Related news from
Thu, 16 Aug 2018
19:06:15 +0000
A Look at Tesaro’s Revenue Trends
Tesaro (TSRO) generated total revenues of $57.21 million in the second quarter. The company generates revenues from product sales and licensing and collaboration activities. Its product sales are comprised of Zejula and Varubi sales.
Thu, 16 Aug 2018
19:06:15 +0000
Understanding Tesaro’s Operational Performance
Tesaro’s (TSRO) selling, general, and administrative expenses increased from $92.98 million in the second quarter of 2017 to $100.03 million in the second quarter of 2018. The increase was due to higher expenses for salaries, benefits, and other personnel-related costs.
Thu, 16 Aug 2018
19:06:15 +0000
Here’s What Tesaro’s Valuation Trend Indicates
Tesaro’s (TSRO) Phase 3 PRIMA trial of Zejula to evaluate it for the treatment of women with newly diagnosed ovarian cancer, irrespective of BRCA mutation status, has been completely enrolled. Its Phase 2 trial of Zejula in combination with an anti-PD-1 antibody in first-line non-small cell lung cancer is ongoing. The company expects to present data in the first half of 2019. In its immuno-oncology pipeline, Tesaro plans to submit a BLA (Biologic License Application) for TSR-042 in 2019.
Thu, 16 Aug 2018
19:06:14 +0000
Analysts’ Expectations for Tesaro and Its Peers in August
Tesaro (TSRO) is a commercial-stage biopharmaceutical company primarily focused on developing treatments for solid tumors by using small molecules and immune-oncology antibodies both as monotherapies and in combinations. Tesaro’s key product, Zejula, has been approved in the United States as well as the European Union as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Tesaro commercialized Zejula in the United States in April 2017 and in Europe in December 2017.
Wed, 15 Aug 2018
09:34:43 +0000
Edited Transcript of TSRO earnings conference call or presentation 2-Aug-18 8:15pm GMT
Q2 2018 TESARO Inc Earnings Call
Mon, 06 Aug 2018
12:49:12 +0000
Is the Options Market Predicting a Spike in Tesaro (TSRO) Stock?
Investors need to pay close attention to Tesaro (TSRO) stock based on the movements in the options market lately.
Mon, 06 Aug 2018
12:02:52 +0000
Tesaro: Lower Fiscal 2018 Guidance, Share Price Fell on August 3
On August 2, Tesaro (TSRO) reported revenues of ~$57.2 million in the second quarter, which is a rise of ~94.2% YoY (year-over-year). The increase was driven by rising demand for ZEJULA, which reported sales of $54 million in the second quarter. The sales were ~107.7% higher on a YoY basis and 10% higher on a sequential basis. For fiscal 2018, Tesaro expects ZEJULA, which is a leading PARP inhibitor in ovarian cancer indication, to report revenues of $225 million–$235 million. Based on the midpoint of the guidance range, the revenue guidance implies YoY growth of ~111% and sequential growth of 10% for ZEJULA.
Mon, 06 Aug 2018
12:00:00 +0000
Today’s Research Reports on Stocks to Watch: Tesaro and Stericycle
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Medical companies Tesaro and Stericycle reported second quarter results last week that sent both stocks tumbling into the red. Both companies lowered their ...
Fri, 03 Aug 2018
20:44:00 +0000
Why Shake Shack, Tesaro, and Square Slumped Today
Find out how poor earnings hit some of these companies hard.
Fri, 03 Aug 2018
20:09:47 +0000
Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree
Tesaro stock crashed to a four-year low Friday after the biotech cut its 2018 outlook and analysts suggested its key drug, Zejula, is struggling to gain traction in the U.S.
Fri, 03 Aug 2018
19:27:00 +0000
A Disappointment Is Sinking Tesaro Shares Today
The commercial-stage biotech has offered up a less-than-optimistic outlook.
Fri, 03 Aug 2018
15:36:00 +0000
Tesaro stock drops 16% on worse-than-expected Q2 results, downbeat guidance
Tesaro Inc. (TSRO) shares dropped 16.3% in extremely heavy Friday morning trade after the company reported a larger-than-expected second-quarter loss and revenue miss, along with downbeat 2018 guidance. The FactSet adjusted earnings-per-share consensus was a loss of $2.63. Revenue rose to $57.21 million from $29.46 million, below the FactSet consensus of $65.5 million.
Fri, 03 Aug 2018
14:22:02 +0000
TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2
TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.
Fri, 03 Aug 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Tesaro and MannKind
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / U.S. equities finished mostly higher on Thursday as Apple breaching the 1 trillion dollar valuation plateau offset the ongoing trade concerns between the U.S. ...
Fri, 03 Aug 2018
00:05:12 +0000
Tesaro (TSRO) Reports Q2 Loss, Lags Revenue Estimates
Tesaro (TSRO) delivered earnings and revenue surprises of -14.29% and -11.29%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Thu, 02 Aug 2018
23:02:53 +0000
Tesaro: 2Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of $3.04. The results did not meet Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment ...
Thu, 02 Aug 2018
20:05:00 +0000
TESARO Announces Second-Quarter 2018 Operating Results
ZEJULA ® Q2 net sales totaled $54 million compared to $26 million for Q2 2017 QUADRA sNDA submission planned for Q4 2018 PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of ...
Thu, 02 Aug 2018
18:15:00 +0000
TESARO, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / TESARO, Inc. (NASDAQ: TSRO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:15 PM Eastern Time. To listen ...
Wed, 01 Aug 2018
01:31:00 +0000
Is Opko Health Getting Its Mojo Back?
Investor optimism appears to be rebounding following a string of disappointments that caused a sharp decline in share prices.
Tue, 31 Jul 2018
12:05:48 +0000
See what the IHS Markit Score report has to say about TESARO Inc.

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This last year I have subscribed to two investment services, ValueForum and a well known income newsletter. ValueForum costs a little over 200 per year. The income newsletter costs about 400 per year. I am up 11% on investments made because I heard about them on ValueForum (of course, I do my own research on everything but the ideas came from ValueForum and there was always some discussion of the pros and cons of each investment on VF). I am down 8% on investments made because I heard about them from the income newsletter. I might also add that I often hear about breaking events immediately on ValueForum and a day or two later the same information is finally available from the newsletter. Hmmm...... which service is the better value?" more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards